Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapy-Implications for Imaging Frequency and Treatment Adaptation.

Bostel T, Sachpazidis I, Splinter M, Bougatf N, Fechter T, Zamboglou C, Jäkel O, Huber PE, Baltas D, Debus J, Nicolay NH.

Front Oncol. 2019 Sep 27;9:940. doi: 10.3389/fonc.2019.00940. eCollection 2019.

2.

Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry.

Lopez Perez R, Münz F, Kroschke J, Brauer J, Nicolay NH, Huber PE.

J Vis Exp. 2019 Sep 1;(151). doi: 10.3791/59968.

PMID:
31524860
3.

Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy.

Lopez Perez R, Münz F, Vidoni D, Rühle A, Trinh T, Sisombath S, Zou B, Wuchter P, Debus J, Grosu AL, Saffrich R, Huber PE, Nicolay NH.

Stem Cell Res. 2019 Oct;40:101536. doi: 10.1016/j.scr.2019.101536. Epub 2019 Aug 13.

4.

IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.

Röhrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg S, Windisch P, Hielscher T, Flechsig P, Floca R, Leitz D, Schuster JP, Huber PE, Debus J, von Deimling A, Lindner T, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2019 Aug 6. doi: 10.1007/s00259-019-04444-y. [Epub ahead of print]

PMID:
31388723
5.

Differential response of esophageal cancer cells to particle irradiation.

Hartfiel S, Häfner M, Perez RL, Rühle A, Trinh T, Debus J, Huber PE, Nicolay NH.

Radiat Oncol. 2019 Jul 8;14(1):119. doi: 10.1186/s13014-019-1326-9.

6.

Impact of dimethyl sulfoxide on irradiation-related DNA double-strand-break induction, -repair and cell survival.

Zwicker F, Hauswald H, Debus J, Huber PE, Weber KJ.

Radiat Environ Biophys. 2019 Aug;58(3):417-424. doi: 10.1007/s00411-019-00797-y. Epub 2019 May 24.

PMID:
31127368
7.

The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Rühle A, Lopez Perez R, Zou B, Grosu AL, Huber PE, Nicolay NH.

Stem Cell Rev Rep. 2019 Jun;15(3):356-373. doi: 10.1007/s12015-019-09886-3. Review.

PMID:
30937640
8.

DNA damage response of clinical carbon ion versus photon radiation in human glioblastoma cells.

Lopez Perez R, Nicolay NH, Wolf JC, Frister M, Schmezer P, Weber KJ, Huber PE.

Radiother Oncol. 2019 Apr;133:77-86. doi: 10.1016/j.radonc.2018.12.028. Epub 2019 Jan 17.

PMID:
30935585
9.

Breast cancer occurrence after low dose radiotherapy of non-malignant disorders of the shoulder.

Zwicker F, Kirchner C, Huber PE, Debus J, Zwicker H, Klepper R.

Sci Rep. 2019 Mar 28;9(1):5301. doi: 10.1038/s41598-019-41725-w.

10.

The influence of a magnetic field on photon beam radiotherapy in a normal human TK6 lymphoblastoid cell line.

Yudhistiara B, Zwicker F, Weber KJ, Huber PE, Ruehle A, Brons S, Haering P, Debus J, Hauswald SH.

Radiat Oncol. 2019 Jan 17;14(1):11. doi: 10.1186/s13014-019-1212-5.

11.

Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey.

El Shafie RA, Weber D, Bougatf N, Sprave T, Oetzel D, Huber PE, Debus J, Nicolay NH.

JMIR Mhealth Uhealth. 2018 Aug 30;6(8):e10916. doi: 10.2196/10916.

12.

Virulence of Flavobacterium psychrophilum isolates in rainbow trout Oncorhynchus mykiss (Walbaum).

Jarau M, Di Natale A, Huber PE, MacInnes JI, Lumsden JS.

J Fish Dis. 2018 Oct;41(10):1505-1514. doi: 10.1111/jfd.12861. Epub 2018 Aug 3.

PMID:
30074253
13.

[Normal tissue: radiosensitivity, toxicity, consequences for planning].

Rühle A, Huber PE.

Radiologe. 2018 Aug;58(8):746-753. doi: 10.1007/s00117-018-0430-4. Review. German.

PMID:
29992402
14.

The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy-induced toxicity.

Rühle A, Huber PE, Saffrich R, Lopez Perez R, Nicolay NH.

Int J Cancer. 2018 Dec 1;143(11):2628-2639. doi: 10.1002/ijc.31619. Epub 2018 Aug 7. Review.

PMID:
29931767
15.

Oncologic Therapy Support Via Means of a Dedicated Mobile App (OPTIMISE-1): Protocol for a Prospective Pilot Trial.

El Shafie RA, Bougatf N, Sprave T, Weber D, Oetzel D, Machmer T, Huber PE, Debus J, Nicolay NH.

JMIR Res Protoc. 2018 Mar 6;7(3):e70. doi: 10.2196/resprot.8915.

16.

The Radiation Resistance of Human Multipotent Mesenchymal Stromal Cells Is Independent of Their Tissue of Origin.

Rühle A, Xia O, Perez RL, Trinh T, Richter W, Sarnowska A, Wuchter P, Debus J, Saffrich R, Huber PE, Nicolay NH.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1259-1269. doi: 10.1016/j.ijrobp.2018.01.015. Epub 2018 Jan 9.

PMID:
29452769
17.

Prospective feasibility analysis of a novel off-line approach for MR-guided radiotherapy.

Bostel T, Pfaffenberger A, Delorme S, Dreher C, Echner G, Haering P, Lang C, Splinter M, Laun F, Müller M, Jäkel O, Debus J, Huber PE, Sterzing F, Nicolay NH.

Strahlenther Onkol. 2018 May;194(5):425-434. doi: 10.1007/s00066-017-1258-y. Epub 2018 Jan 18.

PMID:
29349601
18.

Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab.

Sternlicht MD, Wirkner U, Bickelhaupt S, Lopez Perez R, Tietz A, Lipson KE, Seeley TW, Huber PE.

Respir Res. 2018 Jan 18;19(1):14. doi: 10.1186/s12931-018-0720-4.

19.

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

Münz F, Lopez Perez R, Trinh T, Sisombath S, Weber KJ, Wuchter P, Debus J, Saffrich R, Huber PE, Nicolay NH.

Sci Rep. 2018 Jan 10;8(1):312. doi: 10.1038/s41598-017-18862-1.

20.

Cisplatin radiosensitizes radioresistant human mesenchymal stem cells.

Rühle A, Perez RL, Glowa C, Weber KJ, Ho AD, Debus J, Saffrich R, Huber PE, Nicolay NH.

Oncotarget. 2017 Sep 23;8(50):87809-87820. doi: 10.18632/oncotarget.21214. eCollection 2017 Oct 20.

21.

Low-dose photon irradiation induces invasiveness through the SDF-1α/CXCR4 pathway in malignant mesothelioma cells.

Yamauchi Y, Safi S, Orschiedt L, Gardyan A, Brons S, Rieber J, Nicolay NH, Huber PE, Eichhorn M, Dienemann H, Herth FJF, Weber KJ, Debus J, Hoffmann H, Rieken S.

Oncotarget. 2017 Jul 10;8(40):68001-68011. doi: 10.18632/oncotarget.19134. eCollection 2017 Sep 15.

22.

Tweety-Homolog 1 Drives Brain Colonization of Gliomas.

Jung E, Osswald M, Blaes J, Wiestler B, Sahm F, Schmenger T, Solecki G, Deumelandt K, Kurz FT, Xie R, Weil S, Heil O, Thomé C, Gömmel M, Syed M, Häring P, Huber PE, Heiland S, Platten M, von Deimling A, Wick W, Winkler F.

J Neurosci. 2017 Jul 19;37(29):6837-6850. doi: 10.1523/JNEUROSCI.3532-16.2017. Epub 2017 Jun 12.

23.

Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis.

Bickelhaupt S, Erbel C, Timke C, Wirkner U, Dadrich M, Flechsig P, Tietz A, Pföhler J, Gross W, Peschke P, Hoeltgen L, Katus HA, Gröne HJ, Nicolay NH, Saffrich R, Debus J, Sternlicht MD, Seeley TW, Lipson KE, Huber PE.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw339.

PMID:
28376190
24.

The relative biological effectiveness of carbon ion irradiations of the rat spinal cord increases linearly with LET up to 99 keV/μm.

Saager M, Glowa C, Peschke P, Brons S, Grün R, Scholz M, Huber PE, Debus J, Karger CP.

Acta Oncol. 2016 Dec;55(12):1512-1515. Epub 2016 Nov 9. No abstract available.

PMID:
27827542
25.

Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis.

Dadrich M, Nicolay NH, Flechsig P, Bickelhaupt S, Hoeltgen L, Roeder F, Hauser K, Tietz A, Jenne J, Lopez R, Roehrich M, Wirkner U, Lahn M, Huber PE.

Oncoimmunology. 2015 Dec 29;5(5):e1123366. doi: 10.1080/2162402X.2015.1123366. eCollection 2016 May.

26.

High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer : Experience from a large single-center cohort.

Nicolay NH, Rademacher J, Oelmann-Avendano J, Debus J, Huber PE, Lindel K.

Strahlenther Onkol. 2016 Jul;192(7):458-66. doi: 10.1007/s00066-016-0979-7. Epub 2016 May 31.

PMID:
27245818
27.

Carbon ion radiotherapy decreases the impact of tumor heterogeneity on radiation response in experimental prostate tumors.

Glowa C, Karger CP, Brons S, Zhao D, Mason RP, Huber PE, Debus J, Peschke P.

Cancer Lett. 2016 Aug 10;378(2):97-103. doi: 10.1016/j.canlet.2016.05.013. Epub 2016 May 17.

PMID:
27224892
28.

Mesenchymal stem cells are sensitive to bleomycin treatment.

Nicolay NH, Rühle A, Perez RL, Trinh T, Sisombath S, Weber KJ, Ho AD, Debus J, Saffrich R, Huber PE.

Sci Rep. 2016 May 24;6:26645. doi: 10.1038/srep26645.

29.

Superresolution light microscopy shows nanostructure of carbon ion radiation-induced DNA double-strand break repair foci.

Lopez Perez R, Best G, Nicolay NH, Greubel C, Rossberger S, Reindl J, Dollinger G, Weber KJ, Cremer C, Huber PE.

FASEB J. 2016 Aug;30(8):2767-76. doi: 10.1096/fj.201500106R. Epub 2016 May 10.

PMID:
27166088
30.

Mesenchymal stem cells exhibit resistance to topoisomerase inhibition.

Nicolay NH, Rühle A, Perez RL, Trinh T, Sisombath S, Weber KJ, Schmezer P, Ho AD, Debus J, Saffrich R, Huber PE.

Cancer Lett. 2016 Apr 28;374(1):75-84. doi: 10.1016/j.canlet.2016.02.007. Epub 2016 Feb 11.

PMID:
26876302
31.

Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis.

Askoxylakis V, Hegenbarth P, Timke C, Saleh-Ebrahimi L, Debus J, Röder F, Huber PE.

Radiat Oncol. 2016 Feb 4;11:17. doi: 10.1186/s13014-016-0595-9.

32.

Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin.

Nicolay NH, Lopez Perez R, Rühle A, Trinh T, Sisombath S, Weber KJ, Ho AD, Debus J, Saffrich R, Huber PE.

Sci Rep. 2016 Jan 25;6:20035. doi: 10.1038/srep20035.

33.

Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.

Thieke C, Nicolay NH, Sterzing F, Hoffmann H, Roeder F, Safi S, Debus J, Huber PE.

Radiat Oncol. 2015 Dec 30;10:267. doi: 10.1186/s13014-015-0575-5.

34.

A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial).

Safi S, Beckhove P, Warth A, Benner A, Roeder F, Rieken S, Debus J, Dienemann H, Hoffmann H, Huber PE.

BMC Cancer. 2015 Dec 19;15:988. doi: 10.1186/s12885-015-2006-2.

35.

Intraoperative electron radiation therapy combined with external beam radiation therapy and limb sparing surgery in extremity soft tissue sarcoma: a retrospective single center analysis of 183 cases.

Roeder F, Lehner B, Saleh-Ebrahimi L, Hensley FW, Ulrich A, Alldinger I, Mechtersheimer G, Huber PE, Krempien R, Bischof M, Debus J, Uhl M.

Radiother Oncol. 2016 Apr;119(1):22-9. doi: 10.1016/j.radonc.2015.11.014. Epub 2015 Dec 1.

PMID:
26651593
36.

Long term results of postoperative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of Squamous Cell Carcinoma (SCC) located in the oropharynx or oral cavity.

Hoffmann M, Saleh-Ebrahimi L, Zwicker F, Haering P, Schwahofer A, Debus J, Huber PE, Roeder F.

Radiat Oncol. 2015 Dec 4;10:251. doi: 10.1186/s13014-015-0561-y.

37.

Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.

Flechsig P, Choyke P, Kratochwil C, Warth A, Antoch G, Holland Letz T, Rath D, Eichwald V, Huber PE, Kauczor HU, Haberkorn U, Giesel FL.

Diagn Interv Radiol. 2016 Jan-Feb;22(1):35-9. doi: 10.5152/dir.2015.15220.

38.

Brain tumour cells interconnect to a functional and resistant network.

Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, Weil S, Horstmann H, Wiestler B, Syed M, Huang L, Ratliff M, Karimian Jazi K, Kurz FT, Schmenger T, Lemke D, Gömmel M, Pauli M, Liao Y, Häring P, Pusch S, Herl V, Steinhäuser C, Krunic D, Jarahian M, Miletic H, Berghoff AS, Griesbeck O, Kalamakis G, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W, Winkler F.

Nature. 2015 Dec 3;528(7580):93-8. doi: 10.1038/nature16071. Epub 2015 Nov 4.

PMID:
26536111
39.

TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities.

Schölch S, Rauber C, Weitz J, Koch M, Huber PE.

Oncoimmunology. 2015 May 7;4(11):e1042201. eCollection 2015 Nov.

40.

A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model.

Flechsig P, Kratochwil C, Warth A, Rath D, Eichwald V, Huber PE, Kauczor HU, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2016 Apr;18(2):243-8. doi: 10.1007/s11307-015-0890-0.

PMID:
26330160
41.

Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic.

Nicolay NH, Lopez Perez R, Saffrich R, Huber PE.

Oncotarget. 2015 Aug 14;6(23):19366-80. Review.

42.

Split dose carbon ion irradiation of the rat spinal cord: Dependence of the relative biological effectiveness on dose and linear energy transfer.

Saager M, Glowa C, Peschke P, Brons S, Grün R, Scholz M, Huber PE, Debus J, Karger CP.

Radiother Oncol. 2015 Nov;117(2):358-63. doi: 10.1016/j.radonc.2015.07.006. Epub 2015 Jul 18.

PMID:
26197953
43.

Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.

Blattmann C, Oertel S, Thiemann M, Dittmar A, Roth E, Kulozik AE, Ehemann V, Weichert W, Huber PE, Stenzinger A, Debus J.

Radiat Oncol. 2015 Jul 16;10:146. doi: 10.1186/s13014-015-0455-z.

44.

Mesenchymal stem cells – A new hope for radiotherapy-induced tissue damage?

Nicolay NH, Lopez Perez R, Debus J, Huber PE.

Cancer Lett. 2015 Oct 1;366(2):133-40. doi: 10.1016/j.canlet.2015.06.012. Epub 2015 Jul 9. Review.

PMID:
26166559
45.

High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy.

Jensen AD, Poulakis M, Nikoghosyan AV, Welzel T, Uhl M, Federspil PA, Freier K, Krauss J, Höss A, Haberer T, Jäkel O, Münter MW, Schulz-Ertner D, Huber PE, Debus J.

Radiother Oncol. 2016 Feb;118(2):272-80. doi: 10.1016/j.radonc.2015.05.010. Epub 2015 Jul 8.

PMID:
26164774
46.

Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival.

Jensen AD, Nikoghosyan AV, Poulakis M, Höss A, Haberer T, Jäkel O, Münter MW, Schulz-Ertner D, Huber PE, Debus J.

Cancer. 2015 Sep 1;121(17):3001-9. doi: 10.1002/cncr.29443. Epub 2015 Jun 4.

47.

Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.

Sachpekidis C, Thieke C, Askoxylakis V, Nicolay NH, Huber PE, Thomas M, Dimitrakopoulou G, Debus J, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):127-42. eCollection 2015.

48.

Sublobar Resection, Radiofrequency Ablation or Radiotherapy in Stage I Non-Small Cell Lung Cancer.

Safi S, Rauch G, op den Winkel J, Kunz J, Schneider T, Bischof M, Heussel CP, Huber PE, Herth FJ, Dienemann H, Hoffmann H.

Respiration. 2015;89(6):550-7. doi: 10.1159/000381555. Epub 2015 Apr 30.

49.

Establishment of a patient-derived orthotopic osteosarcoma mouse model.

Blattmann C, Thiemann M, Stenzinger A, Roth EK, Dittmar A, Witt H, Lehner B, Renker E, Jugold M, Eichwald V, Weichert W, Huber PE, Kulozik AE.

J Transl Med. 2015 Apr 30;13:136. doi: 10.1186/s12967-015-0497-x.

50.

Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.

Schölch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M, Huber PE.

Oncotarget. 2015 Mar 10;6(7):4663-76.

Supplemental Content

Loading ...
Support Center